Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Nanologica AB's share price for the quarter that ended in Mar. 2026 was kr0.389. Nanologica AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 121.02 Mil. Therefore, Nanologica AB's market cap for the quarter that ended in Mar. 2026 was kr47.08 Mil.
Nanologica AB's quarterly market cap
declined
from Sep. 2025 (kr101.63 Mil) to Dec. 2025 (kr68.93 Mil) and
declined
from Dec. 2025 (kr68.93 Mil) to Mar. 2026 (kr47.08 Mil).
Nanologica AB's annual market cap
declined
from Dec. 2023 (kr375.92 Mil) to Dec. 2024 (kr160.81 Mil) and
declined
from Dec. 2024 (kr160.81 Mil) to Dec. 2025 (kr68.93 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Nanologica AB's Enterprise Value for Today is kr235.63 Mil.
Nanologica AB (OSTO:NICA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Nanologica AB Market Cap Related Terms
Nanologica AB Market Cap Historical Data
* Premium members only.
The historical data trend for Nanologica AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NICA vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Nanologica AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanologica AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanologica AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Nanologica AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Nanologica AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanologica AB (OSTO:NICA) has a Market Cap of kr155.84 Mil as of Jul. 14, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nanologica AB and its competitors. According to the industry distribution chart, Nanologica AB ranks #1134 out of 1423 companies in the Biotechnology industry, placing it in the top 79.7%.
Is Nanologica AB's Market Cap too high?
Nanologica AB's current Market Cap is kr155.84 Mil. Based on the distribution chart, Nanologica AB ranks #1134 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nanologica AB has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanologica AB ranks #1134 out of 1423 companies for Market Cap. This places Nanologica AB in the lower half of its industry. The industry median Market Cap is 115.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 115.88, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nanologica AB and its competitors. For the Biotechnology industry, the median Market Cap is 115.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanologica AB's current Market Cap is kr155.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (OSTO:NICA) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.24, compared to a current price of kr0.47 — trading 88.8% below its estimated fair value. The current Market Cap is kr155.84 Mil. Nanologica AB's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Nanologica AB (OSTO:NICA), the current Market Cap is kr155.84 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanologica AB (OSTO:NICA) Overvalued in 2026?
Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued.
The current stock price of kr0.47 is trading 88.8% below its estimated GF Value™ of kr4.24.
GuruFocus considers Nanologica AB to be Possible Value Trap.
Key valuation signals for OSTO:NICA:
Market Cap: kr155.84 Mil
GF Value™: kr4.24 vs. price of kr0.47 (88.8% below fair value)
No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
45GF Score
Get the complete analysis for OSTO:NICA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NICA has been successfully added to your 
